

Federal Communications Commission.

**Marilyn Jones,**

*Senior Counsel for Number Administration,  
Wireline Competition Bureau.*

[FR Doc. 2019-26277 Filed 12-4-19; 8:45 am]

**BILLING CODE 6712-01-P**

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting

**TIME AND DATE:** Thursday, December 12, 2019 at 10:00 a.m.

**PLACE:** 1050 First Street NE,  
Washington, DC (12th Floor).

**STATUS:** The December 12, 2019 Open Meeting has been canceled.

**CONTACT PERSON FOR MORE INFORMATION:**  
Judith Ingram, Press Officer, Telephone:  
(202) 694-1220.

Individuals who plan to attend and require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Acting Secretary and Clerk, at (202) 694-1040, at least 72 hours prior to the meeting date.

**Authority:** Government in the Sunshine Act, 5 U.S.C. 552b.

**Laura E. Sinram,**

*Acting Secretary and Clerk of the Commission.*

[FR Doc. 2019-26346 Filed 12-3-19; 4:15 pm]

**BILLING CODE 6715-01-P**

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting

**TIME AND DATE:** Thursday, December 5, 2019 at 10:00 a.m.

**PLACE:** 1050 First Street NE,  
Washington, DC (12th Floor).

**STATUS:** The December 5, 2019 Open Meeting has been canceled.

**CONTACT PERSON FOR MORE INFORMATION:**  
Judith Ingram, Press Officer, Telephone:  
(202) 694-1220.

Individuals who plan to attend and require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Acting Secretary and Clerk, at (202) 694-1040, at least 72 hours prior to the meeting date.

**Authority:** Government in the Sunshine Act, 5 U.S.C. 552b.

**Laura E. Sinram,**

*Acting Secretary and Clerk of the Commission.*

[FR Doc. 2019-26348 Filed 12-3-19; 4:15 pm]

**BILLING CODE 6715-01-P**

## FEDERAL MARITIME COMMISSION

### Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreement under the Shipping Act of 1984. Interested parties may submit comments on the agreements to the Secretary by email at [Secretary@fmc.gov](mailto:Secretary@fmc.gov), or by mail, Federal Maritime Commission, Washington, DC 20573, within twelve days of the date this notice appears in the **Federal Register**. Copies of agreements are available through the Commission's website ([www.fmc.gov](http://www.fmc.gov)) or by contacting the Office of Agreements at (202) 523-5793 or [tradeanalysis@fmc.gov](mailto:tradeanalysis@fmc.gov).

*Agreement No.:* 201325.

*Agreement Name:* Sealand/Network Space Charter Agreement.

*Parties:* Maersk A/S d/b/a Sealand and Network Shipping, Ltd.

*Filing Party:* Wayne Rohde; Cozen O'Connor.

*Synopsis:* The Agreement authorizes Sealand to charter space to Network Shipping in the trade between ports in Ecuador, Panama, Costa Rica, El Salvador, Guatemala, Nicaragua, and Mexico on the one hand and ports in California on the other hand.

*Proposed Effective Date:* 1/11/2020.

*Location:* <https://www2.fmc.gov/FMC/Agreements.Web/Public/AgreementHistory/25450>.

*Dated:* December 2, 2019.

**JoAnne O'Bryant,**

*Program Analyst.*

[FR Doc. 2019-26262 Filed 12-4-19; 8:45 am]

**BILLING CODE 6731-AA-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2018-N-3179]

#### Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting that any industry organizations interested in participating in the selection of nonvoting industry representatives to serve on certain panels of the Medical Devices Advisory Committee (MDAC or Committee) in the Center for Devices and Radiological Health (CDRH) notify FDA in writing. FDA is also requesting nominations for nonvoting industry

representatives to serve on certain device panels of the MDAC in the CDRH. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for current and upcoming vacancies effective with this notice.

**DATES:** Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by January 6, 2020 (see sections I and II of this document for further details). Concurrently, nomination materials for prospective candidates should be sent to FDA by January 6, 2020.

**ADDRESSES:** All statements of interest from industry organizations interested in participating in the selection process of nonvoting industry representative nomination should be sent to Margaret Ames (see **FOR FURTHER INFORMATION CONTACT**). All nominations for nonvoting industry representatives should be submitted electronically by accessing the FDA Advisory Committee Membership Nomination Portal: <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm> or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002. Information about becoming a member of an FDA advisory committee can also be obtained by visiting FDA's website at <https://www.fda.gov/AdvisoryCommittees/default.htm>.

#### FOR FURTHER INFORMATION CONTACT:

Margaret Ames, Division of Management Services, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5213, Silver Spring, MD 20993, 301-796-5960, Fax: 301-847-8505, email: [margaret.ames@fda.hhs.gov](mailto:margaret.ames@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The Agency is requesting nominations for nonvoting industry representatives to the panels listed in the table in this document.

#### I. Medical Devices Advisory Committee

The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. The panels engage in a number of activities to fulfill the functions that the Federal Food, Drug, and Cosmetic Act (FD&C Act) envisions for device advisory panels. With the